Tirzepatide: A Research Reference Guide to the Dual GIP/GLP-1 Agonist
By Lemon Labs Research Desk · Updated June 29, 2026
In short
Tirzepatide is a synthetic peptide that acts as a dual agonist of two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual activity is the defining feature researchers study. It is supplied as a research reference compound only.
What makes tirzepatide distinctive
Most incretin-based research peptides target a single receptor. Tirzepatide is notable because it is engineered to engage two: the GIP receptor and the GLP-1 receptor. Both are part of the incretin system, which research has long associated with glucose-dependent insulin signaling and energy metabolism.
Structurally it is a 39-amino-acid synthetic peptide with a fatty-acid moiety that extends its circulating half-life in pharmacokinetic studies — a feature researchers examine when modeling exposure.
Receptor pharmacology studied in the literature
In receptor-binding and cell-signaling research, tirzepatide has been characterized for its relative potency at GIP versus GLP-1 receptors and the downstream cAMP signaling each pathway drives. The interplay between the two receptors is an active area of mechanistic study and is the main reason tirzepatide is investigated separately from single-agonist peptides.
Why it appears so often in current research
Incretin biology is one of the most heavily studied areas in metabolic science. Tirzepatide and related agonists are among the most searched compounds in this space, which has driven strong demand for well-characterized reference material for laboratory work.
Handling and quality verification
Tirzepatide is supplied lyophilized and stored cold (2–8 °C short term, −20 °C long term), sealed and protected from light. Reconstitution is performed in the lab. Confirm ≥99% purity by HPLC and identity by mass spectrometry against the lot-specific COA.
Research-use-only statement
This compound is supplied strictly for in-vitro research and laboratory use. It is not a drug, supplement, food, or cosmetic, has not been evaluated by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or veterinary use. All information here summarizes published scientific literature for educational purposes for qualified researchers — it is not medical advice and does not describe human administration.
Reference compounds mentioned
Frequently asked
What kind of peptide is tirzepatide?
Tirzepatide is a synthetic dual agonist that activates both the GIP receptor and the GLP-1 receptor. This dual-incretin activity is its defining pharmacological feature in research.
How is tirzepatide different from a GLP-1-only peptide?
A GLP-1-only peptide engages a single incretin receptor, while tirzepatide engages two (GIP and GLP-1). Researchers study how this combined receptor activity differs from single-agonist signaling.
Is research tirzepatide for human use?
No. Material sold as a research reference compound is for in-vitro and laboratory use only — not for human or veterinary use, and not a substitute for any approved product.